NEWS.

In peptide receptor radionuclide therapy, the carrier peptide washes off tumors fast. A redesigned long-acting somatostatin analog, 177Lu-LNC1010, shrank tumors in 44 percent of 18 evaluable patients, but the single-arm trial cannot be compared to the approved drug.

Thymosin alpha-1, an approved immune drug, turns out to dock the orexin receptor on neurons and switch off a death program. In ischemic stroke it protected mouse brains, but the human data is still just a correlation.

A rat study tied one of the worst face pains to a deep brainstem nucleus running a CGRP-RAMP1-PKA signal, the same peptide target migraine drugs block. Silencing the nucleus or blocking the receptor eased the pain, but this is a one-lab mechanism study, not a therapy.

A randomized, double-blind crossover pushed oxytocin in healthy men to twice its natural peak during a graded glucose challenge. C-peptide, glucagon, GIP, GLP-1, and both bone-turnover markers stayed level with placebo. A clean null on a hormone the hype had cast as a quiet metabolic regulator.

A TriNetX study of 56,142 matched pairs found that women over 50 who already had osteoporosis had about half as many collapsed vertebrae (1.9 versus 4.3 percent) and half as many spine surgeries if they took a GLP-1 drug. It is observational, and a relative risk of 0.43 is large enough that healthier patients, not the drug, may explain part of it.

A prospective randomized trial in 174 men with prostate cancer put leuprolide and goserelin head-to-head for a year. Both peptides shut testosterone and PSA down about equally, but the costs diverged: leuprolide brought the sharpest PSA drop along with hot flashes in 90 percent of men and more weight gain, while goserelin ran less steadily and carried more cardiovascular trouble. The takeaway is that two generic LHRH agonists with the same mechanism are not the same clinical decision.

A TriNetX study of 69,222 diabetics found GLP-1 users progressed to trigger-finger surgery slightly less often than matched non-users. There was no difference at six months, and the two-year gap was 1.5 percentage points.

A meta-analysis of 78 observational studies found GLP-1 users developed fewer of ten obesity-linked cancers, with the sharpest numbers coming from comparisons against insulin. Every one of the 78 studies was observational, and the comparator itself marks sicker patients.

A real-world study of 52 children on vosoritide across six Latin American countries (EVOLAC) found height Z-scores climbed more than a full standard deviation over three years, with high adherence and mild side effects. Body proportions stayed flat, there was no control arm, and the surrogate the drug was approved on, growth velocity, is not the skull-base, spinal, or sleep-apnea complications that make achondroplasia dangerous.

In a first-in-human phase Ib trial, a patient's own red blood cells were coated with seven myelin fragments and reinfused. Three months later the immune signature had shifted toward tolerance, with regulatory T cells up and a nerve-damage marker down. Nine patients, no control arm, a single dose.

Injected into the spinal fluid of burned mice, semaglutide relieved pain not by acting directly but by pushing spinal astrocytes to release enkephalins, the body's homemade opioids, at the delta-opioid receptor. It is a mouse study, and the drug's usual under-the-skin route was not tested.

A systematic review found only six human studies of hydrolyzed collagen peptides in tendon and ligament tears. Most used multicomponent products, only one direct-tear study used a clearly defined peptide, and the reviewers call the evidence sparse and low certainty.

A meta-analysis of 25 randomized trials in 8,069 people found GLP-1 drugs cut binge eating, loss of control, and emotional eating. The same drugs pushed deliberate dietary restraint up, and the authors say it is unclear whether that is healthy control or a problem.

In 500 people with type 2 diabetes, those on a GLP-1 drug had roughly a third the odds of painful neuropathy, measured with nerve conduction tests and skin biopsies, not questionnaires. The design is cross-sectional, so protection and patient selection cannot be told apart.

A study in Investigative Ophthalmology and Visual Science found that dry-eye damage drained mouse corneas of CGRP, the nerve-made peptide a whole class of migraine drugs is built to block, and that a topical CGRP eye drop resealed the ocular-surface barrier while quieting its inflammation. Blocking the same peptide was tied to lower glaucoma risk in a migraine cohort, leaving one molecule pulling two directions in the same organ.